Idarucizumab for dabigatran reversal - Does one dose fit all?

Thromb Res. 2016 Oct:146:103-104. doi: 10.1016/j.thromres.2016.09.006. Epub 2016 Sep 13.

Authors

Amihai Rottenstreich¹, Nivin Jahshan², Limor Avraham², Yosef Kalish³

Affiliations

¹ Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
² Coagulation Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
³ Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Electronic address: ykalish@gmail.com.

PMID: 27643848
DOI: 10.1016/j.thromres.2016.09.006

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / therapeutic use*
Dabigatran / administration & dosage
Dabigatran / therapeutic use*
Humans
Male

Substances

Antibodies, Monoclonal, Humanized
idarucizumab
Dabigatran